CED Clinical Relevance #78 Practice-Relevant but Limited Important question, common clinical scenario, but the underlying evidence remains thin, mixed, and hard to standardize.

📋 Clinical Insight | CED Clinic This review is useful because it narrows the question to randomized trials, but it still pulls together very different products, routes, pain states, and comparators. The right read is cautious interest, not clinical certainty.

Evidence Watch Orthopaedics Pain Management Cannabinoids Systematic Review

Audience	Patients, caregivers, clinicians, orthopaedic readers, and evidence-minded cannabis observers
Primary Topic	Cannabis for orthopaedic pain
Source	Read the full article

Cannabis for Orthopaedic Pain: What This 2025 Review Actually Shows

A 2025 systematic review asks an important question about cannabis for orthopaedic pain, but the answer is more restrained than many readers might hope. Across 12 randomized trials, the signal is mixed, often product-specific, usually short-term, and more convincing against placebo than against active medications.

What This Study Teaches Us About Cannabis for Orthopaedic Pain

This is not a new clinical trial. It is a systematic review of 12 randomized, double-blind controlled trials that tried to synthesize what higher-level interventional evidence currently says about cannabis and cannabinoid products in orthopaedic and trauma-related pain.

Its clearest educational value is that it separates broad enthusiasm from the actual shape of the evidence. Some THC-containing or THC:CBD-containing interventions outperformed placebo in selected neuropathic or rheumatic settings, while oral CBD in acute low back pain did not, and active-comparator studies did not provide a clean win for cannabinoids.

It also teaches a more uncomfortable lesson: “orthopaedic pain” sounds like one category, but the review is really pulling together very different conditions, products, doses, and routes of administration. That makes the paper clinically interesting, but much less definitive than the title might suggest.

For the public: Patients in pain are often forced to navigate between medications that feel underwhelming, medications that feel risky, and marketing that sounds much more confident than the data. A review like this matters because it helps readers see where cannabis may be promising, where it may be disappointing, and where the evidence is still too thin to rely on with confidence.

For clinicians: The paper highlights that any conversation about cannabis for orthopaedic pain has to become more specific. Product type, THC exposure, route, pain mechanism, and comparator all seem to matter. The literature does not yet support a single protocol that can be generalized across acute back pain, rheumatoid arthritis, post-traumatic neuropathic pain, and spinal cord injury-related pain.

For researchers and policymakers: This review reinforces a recurring problem in cannabinoid science. Even when investigators limit themselves to randomized trials, the field still suffers from short follow-up, small samples, weak standardization, and inconsistent active-comparator data. That is exactly why headlines often sound more settled than the literature really is.

Study Type	Systematic review of randomized, double-blind controlled trials
Population	Adults across heterogeneous pain states labeled as orthopaedic or trauma-related, including acute non-traumatic low back pain, rheumatoid arthritis, chronic rheumatic pain, brachial plexus avulsion pain, post-traumatic nerve lesions, post-traumatic or postsurgical neuropathic pain, and spinal cord injury-related pain
Exposure or Intervention	A mix of cannabinoid products, including aerosolized THC, oral CBD, nabiximols or Sativex, nabilone, dronabinol, synthetic CT-3, smoked herbal cannabis, and vaporized cannabis
Comparator	Mostly placebo, with limited active comparators such as dihydrocodeine and diphenhydramine
Primary Outcomes	Pain intensity scores, percentage change from baseline, and adverse events, with some secondary reporting on sleep, cognition, mood, and disability
Sample Size or Scope	12 included RCTs, with individual trial sizes ranging from 7 to 125 participants and most downgraded for imprecision
Journal	Cureus
Year	2025
DOI	10.7759/cureus.87208
Funding or Conflicts	The review authors reported no financial support and no current relevant financial relationships. They also note that at least one included trial had industry ties.

This review suggests that some cannabinoid products may help selected forms of pain that sit within the orthopaedic world, especially against placebo, but the evidence is still too inconsistent and too heterogeneous to support broad, standardized clinical use across orthopaedic practice.

The authors searched PubMed and Cochrane for randomized, double-blind controlled trials published from 2003 through 2023 that examined cannabis or cannabinoid products for pain connected to orthopaedic conditions or trauma. They excluded many other pain categories, including fibromyalgia, diabetic neuropathy, multiple sclerosis, cancer pain, and several non-orthopaedic syndromes, in an effort to keep the question narrower and the evidence stronger. They then compared efficacy and safety across studies that used very different cannabinoid formulations, administration routes, durations, and pain scales.

Out of 12 included RCTs, eight were judged superior to control, largely placebo, three were non-superior, and one was inconclusive. Several THC-containing or THC:CBD-containing products showed meaningful pain reduction in selected settings such as neuropathic pain after injury, rheumatoid arthritis, or chronic rheumatic pain. On the other hand, oral CBD for acute low back pain did not outperform placebo, nabilone did not beat dihydrocodeine, and dronabinol did not beat diphenhydramine. Across the paper, the recurring pattern is that cannabis for orthopaedic pain looks more encouraging in some placebo-controlled neuropathic or mixed chronic pain contexts than it does in direct head-to-head comparisons against active medications.

This review does not prove that cannabis works broadly for all orthopaedic pain, that CBD alone is effective for acute back pain, that cannabinoids outperform standard analgesics, or that these products are ready to replace opioids in routine practice. It also does not establish optimal dose, route, duration, functional benefit, bone-healing effects, return-to-activity outcomes, or long-term neurocognitive and pulmonary safety.

This review does not close the case on cannabinoids in orthopaedics. It does, however, support a sober middle ground. Some cannabinoid products may reduce pain in selected conditions, especially compared with placebo, but the current evidence base remains too small, too mixed, and too short-term to justify broad claims. The careful takeaway is interest without overreach.

💬 Join the Conversation

Have a question about how this applies to your situation? Ask Dr. Caplan →

Want to discuss this topic with other patients and caregivers? Join the forum discussion →

Have thoughts on this? Share it:

📰 Source: The Efficacy and Safety of Use of Cannabis and Cannabinoid Products for Pain Relief in Orthopaedic Conditions and Trauma

This Evidence Watch article reviews cannabis for orthopaedic pain, cannabinoids for orthopaedic pain, cannabis and trauma-related pain, medical cannabis for musculoskeletal pain, neuropathic pain after injury, rheumatoid arthritis pain, spinal cord injury pain, low back pain, THC, CBD, nabiximols, nabilone, dronabinol, inhaled cannabis, vaporized cannabis, placebo-controlled pain trials, and the limits of current evidence.

{“@context”:”https://schema.org”,”@type”:”Article”,”headline”:”Cannabis for Orthopaedic Pain: What This 2025 Review Actually Shows”,”about”:”cannabis for orthopaedic pain”,”url”:”https://cedclinic.com/cannabis-for-orthopaedic-pain-review/”,”description”:”Cannabis for orthopaedic pain shows mixed results in a 2025 systematic review, with limited evidence, mild adverse effects, and major clinical gaps.”,”keywords”:[“cannabis for orthopaedic pain”,”cannabinoids for orthopaedic pain”,”cannabis and trauma-related pain”,”medical cannabis for musculoskeletal pain”,”orthopaedic pain”,”neuropathic pain”,”systematic review”,”Evidence Watch”],”author”:{“@type”:”Person”,”name”:”Dr. Benjamin Caplan, MD”},”publisher”:{“@type”:”Organization”,”name”:”CED Clinic”,”url”:”https://cedclinic.com/”},”mainEntityOfPage”:”https://cedclinic.com/cannabis-for-orthopaedic-pain-review/”}

{“@context”:”https://schema.org”,”@type”:”FAQPage”,”mainEntity”:[{“@type”:”Question”,”name”:”Is this paper a new clinical trial?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”No. It is a systematic review that combines and evaluates previously published randomized controlled trials.”}},{“@type”:”Question”,”name”:”How many studies were included?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”Twelve randomized, double-blind controlled trials met the authors’ inclusion criteria.”}},{“@type”:”Question”,”name”:”Did the review find that cannabinoids always worked?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”No. Some products outperformed placebo in selected settings, but several trials were negative or inconclusive.”}},{“@type”:”Question”,”name”:”Did CBD alone look effective here?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”Not convincingly. In the included oral CBD trial for acute low back pain, CBD did not outperform placebo.”}},{“@type”:”Question”,”name”:”Did cannabis-based treatments beat standard active medications?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”Not reliably. The active-comparator trials in this review did not show clear superiority for cannabinoids.”}},{“@type”:”Question”,”name”:”What side effects were most common?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”Most reported adverse effects were mild to moderate, with dizziness, sedation, and other neurologic symptoms appearing often.”}},{“@type”:”Question”,”name”:”Does this apply to all orthopaedic pain conditions?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”No. The included conditions were heterogeneous, and many centered on neuropathic or rheumatic pain rather than the full range of orthopaedic problems.”}},{“@type”:”Question”,”name”:”Does this review prove cannabinoids should replace opioids?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”No. It suggests possible adjunctive value, but it does not establish cannabinoids as a universal opioid replacement strategy.”}},{“@type”:”Question”,”name”:”Does the paper identify the best dose or route?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”No. The products, doses, and administration routes were too inconsistent to support a standard protocol.”}},{“@type”:”Question”,”name”:”What is the fairest bottom-line takeaway?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”There may be real therapeutic potential here, but the evidence remains mixed, condition-specific, and not yet robust enough for broad claims.”}}]}